Whole Genetic Code of IVF Embryos Scanned for Mutations
By LabMedica International staff writers Posted on 23 Feb 2015 |
Image: A completely hatched blastocyst of high quality for in vitro fertilization (Photo courtesy of Dr. Richard Sherbahn MD).
Currently, the methods available for preimplantation genetic diagnosis (PGD) of in vitro fertilized (IVF) embryos do not detect de novo single-nucleotide and short indel mutations, which have been shown to cause a large fraction of genetic diseases.
The detection and phasing of single base de novo mutations in biopsies from human in vitro fertilized embryos by advanced whole-genome sequencing has been accomplished and the technique would enable couples to use IVF for the conception of children who otherwise would have inherited devastating mitochondrial diseases.
Genomic scientists at Complete Genomics, Inc. (Mountain View, CA, USA) and their colleagues used a new technique that allows the whole genome of IVF embryos to be scanned via the cells of 10 biopsies. The team said the testing is the first to be able to detect all the new genetic mutations that happen uniquely in an individual, as opposed to only those that have been handed down from parents.
Using up to just 10 cells to do the whole-genome sequencing means the DNA has to be amplified, which can introduce errors. However, the scientists working with another commercial team from Reprogenetics (Livingston, NJ, USA), used the technique at a fertility center to remove any falsely identified genetic mutations. They applied their "long fragment read" technology, using DNA barcodes to assign DNA fragments to the embryos' maternal or paternal genome. They were able to remove over 100,000 sequencing errors, reducing the error rate approximately 100-fold over previous studies.
The technique means the 5-day-old, blastocyst-stage embryos could be scanned for de novo mutations, those arising spontaneously in the egg or sperm and not inherited from either parent. In one embryo in the study, the scientists did not find any de novo mutations in the regions of the genome that code for proteins. In the other embryo from the couple, however, they picked up two coding mutations in the zinc finger protein 266 (ZNF266) and the solute carrier family 26, (SLC26A10) genes that may be potentially damaging.
The authors concluded that the biggest hurdle now is one of how to analyze the medical impact of detected mutations and make decisions based on those results. Whole-genome sequencing using barcoded DNA could be used in the future as part of the preimplantation genetic diagnosis process to maximize comprehensiveness in detecting disease-causing mutations and reduce the incidence of genetic diseases. The study was published on February 11, 2015, in the journal Genome Research.
Related Links:
Complete Genomics, Inc.
Reprogenetics
The detection and phasing of single base de novo mutations in biopsies from human in vitro fertilized embryos by advanced whole-genome sequencing has been accomplished and the technique would enable couples to use IVF for the conception of children who otherwise would have inherited devastating mitochondrial diseases.
Genomic scientists at Complete Genomics, Inc. (Mountain View, CA, USA) and their colleagues used a new technique that allows the whole genome of IVF embryos to be scanned via the cells of 10 biopsies. The team said the testing is the first to be able to detect all the new genetic mutations that happen uniquely in an individual, as opposed to only those that have been handed down from parents.
Using up to just 10 cells to do the whole-genome sequencing means the DNA has to be amplified, which can introduce errors. However, the scientists working with another commercial team from Reprogenetics (Livingston, NJ, USA), used the technique at a fertility center to remove any falsely identified genetic mutations. They applied their "long fragment read" technology, using DNA barcodes to assign DNA fragments to the embryos' maternal or paternal genome. They were able to remove over 100,000 sequencing errors, reducing the error rate approximately 100-fold over previous studies.
The technique means the 5-day-old, blastocyst-stage embryos could be scanned for de novo mutations, those arising spontaneously in the egg or sperm and not inherited from either parent. In one embryo in the study, the scientists did not find any de novo mutations in the regions of the genome that code for proteins. In the other embryo from the couple, however, they picked up two coding mutations in the zinc finger protein 266 (ZNF266) and the solute carrier family 26, (SLC26A10) genes that may be potentially damaging.
The authors concluded that the biggest hurdle now is one of how to analyze the medical impact of detected mutations and make decisions based on those results. Whole-genome sequencing using barcoded DNA could be used in the future as part of the preimplantation genetic diagnosis process to maximize comprehensiveness in detecting disease-causing mutations and reduce the incidence of genetic diseases. The study was published on February 11, 2015, in the journal Genome Research.
Related Links:
Complete Genomics, Inc.
Reprogenetics
Latest Molecular Diagnostics News
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset